Progestogen Lactone Derivatives for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current progestogen compounds like drospirenone suffer from low aqueous solubility and susceptibility to isomerization, leading to reduced bioavailability and increased side effects in contraceptive and hormone replacement therapies.
Innovation Solution
Development of novel 3-(6,6-ethylene-17β-hydroxy-3-oxo-17α-pregna-4-ene-17α-yl)propionic acid γ-lactone derivatives with improved solubility and stability, including specific structural formulas (II, III, IV, V) that enhance bioavailability and reduce side effects when administered in oral dosage forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If drospirenone is used as a progestogen compound, then progestational and antialdosterone activity is achieved, but aqueous solubility is low leading to reduced bioavailability
Solution Approach 1:
The patent modifies the chemical structure of drospirenone by introducing a double bond at either the 9,11-position or 11,12-position of the steroid nucleus. This structural parameter change fundamentally alters the molecule's properties: the new compounds exhibit significantly improved aqueous solubility and stability in gastric conditions while maintaining the desired progestational and antialdosterone biological activity. The parameter change approach directly resolves the contradiction by changing the molecular structure to achieve both solubility and activity.
2Reliability
If 17α spirolactones are used, then progestational and antialdosterone activity is achieved, but susceptibility to isomerization under acidic conditions reduces effectiveness
Solution Approach 1:
The patent introduces a double bond at the 9,11 or 11,12 position of the steroid nucleus, which fundamentally changes the molecule's chemical stability profile. This parameter change makes the compound resistant to acid-catalyzed isomerization that plagues conventional 17α spirolactones. The new structural parameter maintains the essential pharmacological activity while providing stability in the acidic gastric environment, directly resolving the contradiction between activity and stability.
3Quantity of substance
If higher dosages of 17α spirolactones are used to counteract inactivation, then adequate bioavailability is achieved, but side effects increase
Solution Approach 1:
By changing the structural parameters of the progestogen compound (introducing the 9,11 or 11,12 double bond), the patent creates a molecule with improved intrinsic properties: higher aqueous solubility and gastric stability. This allows adequate bioavailability to be achieved at lower dosages, thereby reducing the incidence of dose-dependent side effects such as depression, nausea, and thrombosis risk. The parameter change enables effective dosing without the harmful effects of high dosages.
Data Source
AI summary
Described herein are 3-(6,6-ethylene-17β-hydroxy-3-oxo-17α-pregna-4-ene-17α-yl)propionic acid γ-lactone derivatives having progestational and aldosterone antagonistic activity. Also described herein are methods of preparing and using these novel compounds.